← GLP-1 receptor agonists × quality of life & behaviour

TrialDiabetes, obesity & metabolism2019

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT01179048. The trial’s primary report, PMID 27295427, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedrandomised · 2019

Randomised comparison

Probably raised quality of life & behaviour

Doesn’t vote: a later paper about the trial

+0.02+0.00 to +0.04

As reported

difference 0.023, 95% CI 0.00–0.04

One number in the abstract

the abstract, start to end

… estimated treatment difference [ETD] 0.023, 95% confidence interval [CI] …

← favours treatmentfavours comparator →
could be chance
Quality of life & behaviour
0.0230.00–0.04
GLP-1 receptor agonistsQuality of life & behaviour
1 / 3

21 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01179048phase 39,341 enrolled2010a later paper about it
Full record →Abstract, authors, funding and every citing paper · PMID 30260088